This user has not added any information to their profile yet.
Company Profile
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2021, Boehringer Ingelheim stepped up annual investments in R&D to a new high in history. The company spent 4.1 billion EUR on R&D. Boehringer Ingelheim recorded net sales of 20.6 billion EUR (2020: 19.6 billion EUR), a 5.4% increase compared to the previous year.
Under the ‘Sustainable Development – For Generations’ framework, Boehringer Ingelheim has globally pledged 250 million EUR to combat infectious diseases in humans and animals and expanding healthcare access for non-communicable diseases for 50 million people in vulnerable communities, including in the ASKAN area. In addition to improving across-the-board access to healthcare, Boehringer Ingelheim is committed to carbon neutrality by 2030 and is taking bold steps to address the growing burden of food security and safety to build a sustainable and healthy future for all.
For more information, please visit www.boehringer-ingelheim.com
Company Information
Company Description
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2021, Boehringer Ingelheim stepped up annual investments in R&D to a new high in history. The company spent 4.1 billion EUR on R&D. Boehringer Ingelheim recorded net sales of 20.6 billion EUR (2020: 19.6 billion EUR), a 5.4% increase compared to the previous year.
Under the ‘Sustainable Development – For Generations’ framework, Boehringer Ingelheim has globally pledged 250 million EUR to combat infectious diseases in humans and animals and expanding healthcare access for non-communicable diseases for 50 million people in vulnerable communities, including in the ASKAN area. In addition to improving across-the-board access to healthcare, Boehringer Ingelheim is committed to carbon neutrality by 2030 and is taking bold steps to address the growing burden of food security and safety to build a sustainable and healthy future for all.
For more information, please visit www.boehringer-ingelheim.com
Business Category
Number of Employees in Vietnam
Company Name
Address
Telephone
2nd Address
2nd Telephone
Fax
Website
Log in as a member to access the details. Not a member? Contact our Membership team at (84-28) 3827 2715 ext 105 or membership@eurochamvn.org
This user has not added any information to their profile yet.
Company Profile
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2021, Boehringer Ingelheim stepped up annual investments in R&D to a new high in history. The company spent 4.1 billion EUR on R&D. Boehringer Ingelheim recorded net sales of 20.6 billion EUR (2020: 19.6 billion EUR), a 5.4% increase compared to the previous year.
Under the ‘Sustainable Development – For Generations’ framework, Boehringer Ingelheim has globally pledged 250 million EUR to combat infectious diseases in humans and animals and expanding healthcare access for non-communicable diseases for 50 million people in vulnerable communities, including in the ASKAN area. In addition to improving across-the-board access to healthcare, Boehringer Ingelheim is committed to carbon neutrality by 2030 and is taking bold steps to address the growing burden of food security and safety to build a sustainable and healthy future for all.
For more information, please visit www.boehringer-ingelheim.com
Company Information
